Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of peritoneal fibrosis in peritoneal dialysis patients
ChiCTR2400092824Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui University of Chinese Medicine
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in end-stage kidney disease (ESKD) and peritoneal fibrosis (PF) (2 arms), sponsored by First Affiliated Hospital of Anhui University of Chinese Medicine. Primary endpoints: 24-hour urine output at 12 months, Peritoneal ultrafiltration volume at 12 months and 3 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
end-stage kidney disease (ESKD)peritoneal fibrosis (PF)
Beyond the preview
Go deeper on ChiCTR2400092824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092824.